Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Innovations

Intensity Therapeutics, a late-stage clinical biotechnology company, has successfully raised $6.6 million in gross proceeds through an At-the-Market (ATM) offering, selling 19,868,658 shares of its common stock at an average price of $0.3323 per share. This financial boost enhances the company's ability to continue its groundbreaking clinical trials into the second half of 2026, focusing on the development of innovative intratumoral cancer therapies.

The company's proprietary non-covalent conjugation technology is at the heart of its research, aiming to kill tumors and enhance the immune system's ability to recognize cancers. Lewis H. Bender, President and CEO of Intensity Therapeutics, highlighted the strategic advantage of the ATM sales, noting the average price per share was more than 10% higher than the company's recent public offering in June 2025, with significantly lower capital-raising costs.

Intensity Therapeutics' lead investigational product, INT230-6, represents a promising advancement in cancer treatment. Designed for direct intratumoral injection, INT230-6 utilizes the company's DfuseRx℠ technology platform to deliver a potent combination of anti-cancer agents directly into tumors, facilitating a targeted attack on cancer cells while minimizing systemic side effects. This approach not only aims for local disease control but also stimulates an immune response against the cancer, offering a potential paradigm shift in treatment strategies.

The company's clinical trials, including Phase 1/2 and Phase 2 studies, have already enrolled over 200 patients, testing INT230-6 in various cancer types. With the initiation of a Phase 3 trial in soft tissue sarcoma and a Phase 2 study in triple-negative breast cancer, Intensity Therapeutics is at the forefront of developing treatments that could turn deadly cancers into manageable conditions. For more information on Intensity Therapeutics and its innovative research, visit https://www.intensitytherapeutics.com.

This funding milestone not only underscores the confidence in Intensity Therapeutics' innovative approach to cancer treatment but also highlights the potential impact of its research on patients worldwide. By advancing its clinical trials, the company moves closer to offering new hope for those battling cancers resistant to conventional therapies.